Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6719670 | 0.90 | IDO1 (0.41) | IDO1APPALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL6717128 | 0.87 | SLC6A4 (0.42) | IDO1APPALDH1A1L3MBTL1ABCB1 | |
| SCHEMBL6721585 | 0.87 | IDO1 (0.38) | IDO1APPALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL6728445 | 0.83 | KDM4E (0.41) | IDO1GAAALDH1A1KDM4E | |
| SCHEMBL6721773 | 0.82 | IDO1 (0.43) | IDO1APPGAAALDH1A1L3MBTL1 | |
| SCHEMBL6717622 | 0.78 | IDO1 (0.39) | IDO1APPALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL13584342 | 0.75 | MCHR1 (0.38) | — | |
| SCHEMBL6720004 | 0.72 | L3MBTL1 (0.42) | IDO1APPANO1KDM4EL3MBTL1 | |
| SCHEMBL3539341 | 0.68 | ACHE (0.44) | APPALDH1A1KDM4E | |
| SCHEMBL17366270 | 0.68 | MCHR1 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | IDO1 4197/4885APP 1385/4885ANO1 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.